UroToday20h
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday1d
ASCO 2022: Final Clinical Results of Pivotal Trial of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary NMIBC
(UroToday.com) The 2022 ASCO annual meeting featured an oral abstract session on kidney and bladder cancer, including a presentation by Dr. Karim Chamie discussing the final results of the trial ...
UroToday3d
Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Reno, Nevada (UroToday.com) Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve ...
UroToday4d
ASTRO 2024: The RAVENS Phase 2 Randomized Trial: Outcomes of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS
(UroToday.com) The 2024 ASTRO annual meeting included a late-breaking abstract session, featuring a presentation by Dr. Ana Kiess discussing outcomes of the RAVENS phase 2 randomized trial assessing ...
UroToday4d
Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma.
Upper tract urothelial carcinoma (UTUC) is an aggressive entity with treatment strategies mirroring bladder cancer. Genomic and molecular profiling allows for a better characterization of this disease ...
UroToday4d
Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer.
This review explores the current landscape of treatments which target the DNA damage response (DDR) in metastatic and muscle-invasive bladder cancer. It emphasizes recent clinical trials which ...
UroToday4d
Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.
Prostate cancer therapies against androgen receptor (AR) eventually develop lethal resistance; thus, exploring new therapeutic approaches is urgent for prostate cancer treatment. Acetyltransferase ...
UroToday4d
Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients.
The aim of this study was to test for the association between paraplegia and perioperative complications as well as in-hospital mortality after radical cystectomy (RC) for non-metastatic bladder ...
UroToday4d
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial.
Delivering radiotherapy to the bladder is challenging as it is a mobile, deformable structure. Dose-escalated adaptive image-guided radiotherapy could improve outcomes. RAIDER aimed to demonstrate the ...
UroToday4d
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer.
Men with localized prostate cancer may receive either photon-based intensity-modulated radiotherapy (IMRT) or proton beam therapy (PBT). The XXXXX trial (NCT01617161), demonstrates the feasibility of ...
UroToday4d
European Society for Medical Oncology (ESMO) 2024 Quick Takes
(UroToday.com) The House of Delegates (HOD) convened at the American Medical Association (AMA) Annual Meeting in Chicago, IL, in June 2024. During the HOD, voting members of the legislative body of ...
UroToday5d
Disparities and Underutilization of Aggressive Therapy in Muscle-Invasive Bladder Cancer: An NCDB Analysis
Ashish Kamat and Siamak Daneshmand discuss research on racial differences in tumor detection using blue light cystoscopy. The study reveals that while blue light enhances tumor detection universally, ...